Fig. 4

MiR-3064 targets PIP4K2B and represses its expression in PC cells. (a) The predicted binding sites between miR-3064 and PIP4K2B 3′-UTR. (b) qRT-PCR analysis of miR-3064 expression in PC tissues and normal tissues. (c) Analysis of PIP4K2B expression in PC tissues and normal tissues using the TCGA data obtained from the UALCAN database. (d, e) miR-3064 expression in PCs classified by tumor stages (d) and grades of differentiation (e) according to UALCAN database. (f) Association of PIP4K2B expression with overall survival in PC patients using the KMplotter database. (g) Examination of PIP4K2B expression in PC cell lines and a normal pancreatic cell line HPDE6-C7 using qRT-PCR assays. (h) The luciferase activity in AsPC-1 cells cotransfected with reporter vectors containing wild type (WT) or mutant (MUT) PIP4K2B 3′-UTR, together with or without miR-3064 mimic, and in PaCa-2 cells cotransfected with reporter vectors containing wild type or mutant PIP4K2B 3′-UTR, together with or without miR-3064 inhibitor. (i) The protein levels of PIP4K2B in AsPC-1 cells transfected with or without miR-3064 mimic, and in PaCa-2 cells transfected with or without miR-3064 inhibitor. *P < 0.05